Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
tinodasertib (AUM001) / AUM Biosci
KEYNOTE-D65, NCT05462236: MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer	Recruiting	2	120	RoW	Tinodasertib, AUM001, Pembrolizumab, KEYNOTE-D65, KEYTRUDA®, Irinotecan	AUM Biosciences Pte Ltd, Merck Sharp & Dohme LLC	Metastatic Colorectal Cancer	09/24	10/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
tinodasertib (AUM001) / AUM Biosci
KEYNOTE-D65, NCT05462236: MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer	Recruiting	2	120	RoW	Tinodasertib, AUM001, Pembrolizumab, KEYNOTE-D65, KEYTRUDA®, Irinotecan	AUM Biosciences Pte Ltd, Merck Sharp & Dohme LLC	Metastatic Colorectal Cancer	09/24	10/26